Fig. 1From: Multi-criteria decision analysis (MCDA): testing a proposed MCDA framework for orphan drugsOverall drug scores based on the proposed MCDA framework. PAH: Pulmonary arterial hypertension; MPS II: Mucopolysaccharidosis II; LGS: Lennox-Gastaut syndrome; MPS VI: Mucopolysaccharidosis VI; PNH: Paroxysmal nocturnal haemoglobinuria; MDS: Myelodysplastic syndromes Back to article page